BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript

SA Transcripts 162.01K Followers Follow BioArctic AB (publ) ( BRCTF ) Q2 2026 Earnings Call August 26, 2026 3:30 AM EDT Company Participants Gunilla Osswald - President & CEO Johanna Fälting - Chief R&D Officer and Head of Research & Development Anna-Kaija Gronblad - Chief Commercial Officer & Head of Commercial Operations Anders Martin-Lof - Secretary of the Board & CFO Conference Call Participants Joseph Hedden - Rx Securities Limited, Research Division Chenxiao Da - Goldman Sachs Group, Inc., Research Division Mattias Haggblom Presentation Operator Welcome to BioArctic Q2 Report 2026. [Operator Instructions] Now I will hand the conference over to CEO, Gunilla Osswald, with colleagues. Please go ahead. Gunilla Osswald President & CEO Thank you so much, and good morning, and welcome to BioArctic's presentation for the second quarter of 2026. Leqembi continues to progress really well with new approvals and launches. And BioArctic has signed additional strategic partnerships, and we will talk more about this in today's webcast. Next slide, please. BioArctic is listed at Nasdaq Stockholm Large Cap, and this is our disclaimer. Next slide, please. I'm Gunilla Osswald, the CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Lof; and our Chief R&D Officer, Johanna Falting; and our Chief Commercial Officer, Anna-Kaija Gronblad. Next slide, please. I will start our presentation by giving some key highlights. Next slide, please. BioArctic is among world leaders in 2 different areas. The first one is regarding highly selective antibodies where we are innovative and we are generating highly selective antibodies targeting aggregated misfolded forms of toxic proteins. And here, we have the frontrunner lecanemab, and we also have projects targeting alpha-synuclein and TDP-43, for example. The second area is when we are utilizing our BrainTransporter platform in an innovative and differentiated way to deliver antibodies. And I also want to highlight that we are broadening the platform to enable more efficient transportation into the brain